Maravai LifeSciences
MRVI
217 hedge funds and large institutions have $1.2B invested in Maravai LifeSciences in 2024 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 67 increasing their positions, 67 reducing their positions, and 34 closing their positions.
822% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $236K
35% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 34
13% more capital invested
Capital invested by funds: $1.06B → $1.2B (+$142M)
6% more funds holding
Funds holding: 205 → 217 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 67
9.12% less ownership
Funds ownership: 110.93% → 101.81% (-9.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$32.3M |
| 2 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
+$23M |
| 3 |
Goldman Sachs
New York
|
+$14M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.8M |
| 5 |
Morgan Stanley
New York
|
+$8.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$34.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.5M |
| 3 |
PE
Point72 Europe
London,
United Kingdom
|
-$17.7M |
| 4 |
Millennium Management
New York
|
-$14.2M |
| 5 |
Jennison Associates
New York
|
-$13.6M |
MRVI Hedge Fund Activity: Q3 2024 in Review
217 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2024, worth a combined $1.2B — up 13% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MRVI positions and 34 closed out — a net gain of 12 holders — while 67 added to existing stakes and 67 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $32.3M. The largest seller was Marshall Wace, cutting an estimated $34.5M.
- 217 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2024, up from 205 in Q2 2024.
- Funds reported $1.2B of Maravai LifeSciences stock for Q3 2024, up 13% quarter-over-quarter.
- 46 funds opened new Maravai LifeSciences positions in Q3 2024 and 34 closed out, a net change of +12 holders.
- The largest Maravai LifeSciences buyer in Q3 2024 was JP Morgan Chase, an estimated $32.3M added.
- The largest Maravai LifeSciences seller in Q3 2024 was Marshall Wace, an estimated $34.5M sold.
Based on aggregated 13F filings for Q3 2024.